MDT

85.25

-1.98%↓

112.89

+0.95%↑

VEEV

175.24

-0.3%↓

HQY

82.47

-0.59%↓

CSBR

5.65

-0.18%↓

MDT

85.25

-1.98%↓

112.89

+0.95%↑

VEEV

175.24

-0.3%↓

HQY

82.47

-0.59%↓

CSBR

5.65

-0.18%↓

MDT

85.25

-1.98%↓

112.89

+0.95%↑

VEEV

175.24

-0.3%↓

HQY

82.47

-0.59%↓

CSBR

5.65

-0.18%↓

MDT

85.25

-1.98%↓

112.89

+0.95%↑

VEEV

175.24

-0.3%↓

HQY

82.47

-0.59%↓

CSBR

5.65

-0.18%↓

MDT

85.25

-1.98%↓

112.89

+0.95%↑

VEEV

175.24

-0.3%↓

HQY

82.47

-0.59%↓

CSBR

5.65

-0.18%↓

Начало・Списък с акции・Vaxart Inc

Vaxart Inc

Отворен

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

Максимум

Ключови измерители
By Trading Economics
Приходи	63M 55M
Продажби	32M 104M
P/E Средно за сектора	10.286 57.05
EPS	0.24
Марж на печалбата	52.807
Служители	65
EBITDA	63M 58M

Дивиденти
By Dow Jones
Следващи печалби	12.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-19M 173M
Предишно отваряне	0
Предишно затваряне	0

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

0.4007 / 0.4252 Подкрепа & съпротива

Vaxart Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

30.03.2026 г., 23:15 ч. UTC

Значими събития в новините

U.K. Shoppers Paid a Little More This Month But Worse May yet Lie Ahead

30.03.2026 г., 22:36 ч. UTC

Значими събития в новините

Australian Government Rules Out Boots on the Ground in the Middle East

30.03.2026 г., 22:13 ч. UTC

Придобивния, сливания и поглъщания

Sun Life Financial Agrees to Buy Bell Partners for $350 Million

30.03.2026 г., 21:00 ч. UTC

Печалби

Aktis Oncology Gets FDA Clearance for Phase 1 Billion Trial of Tumor Treatment

30.03.2026 г., 20:15 ч. UTC

Значими събития в новините

Fed's Williams: Middle-East Developments Have Added Significant Economic Uncertainty

30.03.2026 г., 23:40 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

30.03.2026 г., 23:40 ч. UTC

Пазарно говорене

Nikkei May Decline on Higher Energy Cost Concerns -- Market Talk

30.03.2026 г., 23:36 ч. UTC

Пазарно говорене

Gold Edges Lower Amid Divergent Signals on U.S.-Iran Talks -- Market Talk

30.03.2026 г., 23:12 ч. UTC

Пазарно говорене

Alcoa Earnings Outlook Boosted by Market Disruptions -- Market Talk

30.03.2026 г., 22:49 ч. UTC

Пазарно говорене

Fed's Williams: Core Inflation Forecast Is Little Changed -- Market Talk

30.03.2026 г., 22:44 ч. UTC

Пазарно говорене

Fed's Williams: Risks to Both Sides of Dual Mandate Higher -- Market Talk

30.03.2026 г., 22:43 ч. UTC

Пазарно говорене

Fed's Williams Says Focus Is on Inflation Expectations Being Well Anchored -- Market Talk

30.03.2026 г., 22:42 ч. UTC

Пазарно говорене

South32 Should Go for Growth, Says New Bull -- Market Talk

30.03.2026 г., 22:18 ч. UTC

Пазарно говорене

Paragon Care's Chances of Using Levy to Pass on Higher Costs `Close to Zero' -- Market Talk

30.03.2026 г., 22:05 ч. UTC

Пазарно говорене

Northern Star's New Bull Argues Case for Asset Sales -- Market Talk

30.03.2026 г., 21:58 ч. UTC

Придобивния, сливания и поглъщания

Sun Life Financial Agrees to Buy Bell Partners for $350M

30.03.2026 г., 21:39 ч. UTC

Придобивния, сливания и поглъщания

Sun Life Sees 1Q Charge to Net of C$236M From BGO, Crescent Deals

30.03.2026 г., 21:38 ч. UTC

Придобивния, сливания и поглъщания

Sun Life: Completes Remaining Equity Interest Purchases of BGO, Crescent Capital

30.03.2026 г., 21:36 ч. UTC

Придобивния, сливания и поглъщания

Sun Life to Buy Fully Bell Partners for $350M >SLF.T

30.03.2026 г., 21:33 ч. UTC

Придобивния, сливания и поглъщания

Unilever Shareholders Expected to Own Two-Thirds of New Food Entity, Sources Say -- WSJ

30.03.2026 г., 21:33 ч. UTC

Придобивния, сливания и поглъщания

Unilever Nears Deal to Create $60 Billion Food Giant With McCormick -- WSJ

30.03.2026 г., 21:33 ч. UTC

Придобивния, сливания и поглъщания

Deal Could Be Announced As Soon As Tuesday, Sources Say -- WSJ

30.03.2026 г., 21:33 ч. UTC

Придобивния, сливания и поглъщания

Unilever Nears Cash-and-Stock Deal to Combine Food Business With McCormick, Sources Say -- WSJ

30.03.2026 г., 21:33 ч. UTC

Придобивния, сливания и поглъщания

Deal Set to Value Combined Food Business At Around $60B Including Debt, Sources Say -- WSJ

30.03.2026 г., 21:25 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

30.03.2026 г., 21:25 ч. UTC

Пазарно говорене

Warehouse Showing Cost Discipline But Margin Goal at Risk -- Market Talk

30.03.2026 г., 21:03 ч. UTC

Придобивния, сливания и поглъщания

Sun Life: Completes Equity Interest Purchases of BGO and Crescent Cap, Announces Acquisition of Bell Partners, a Multifamily Real Estate Investment Manager

30.03.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

30.03.2026 г., 20:09 ч. UTC

Печалби

This Stock Looks Like a Solid AI Bet -- and Wall Street Hasn't Noticed Yet -- Barrons.com

30.03.2026 г., 20:00 ч. UTC

Значими събития в новините

Fed's Williams: Middle-East Conflict 'Will Likely Boost Overall Inflation in Coming Months'

Сравнение с други в отрасъла

Ценова промяна

Vaxart Inc Прогноза

Консенсусна оценка

By TipRanks

0 ratings

Купи

Задържане

Продай

Според 0 анализатори, дали борсови рейтинги на Vaxart Inc през последните 3 месеца.

Техническа оценка

By Trading Central

0.4007 / 0.4252Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There is one bearish event.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Vaxart Inc

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.